- Credit Suisse analyst Kaumil Gajrawala downgraded Clorox Co (NYSE:CLX) to Underperform from Neutral with a $160 price target.
- The analyst thinks a large portion of Clorox’s growth during the first phase of the pandemic came from categories that are now declining.
- If consumption continues to revert toward pre-pandemic levels, $500 million in company sales may still be at risk, Gajrawala notes.
- The analyst also believes margins may take longer to recover due to uncertainty around pricing and elasticities.
- If consumption weakens further amid high input cost inflation, a drop in volumes could result in material de-leverage to margins, the analyst adds.
- Price Action: CLX shares are trading lower by 4.84% at $166.08 on the last check Wednesday.
GT Biopharma Announces Updated Safety Data From Phase 1 GTB-3550 Monotherapy TriKE Trial An Investigational Immunotherapy For Refractory Cancers To Be Presented at ESMO Congress 2021
GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager,
